New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 12, 2009, Pages 1337-1343

  Cadavid, D ^a   Cheriyan, J ^a   Skurnick, J ^a   Lincoln, J A ^a   Wolansky, L J ^a   Cook, S D ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; INTERFERON BETA SERINE;

ARTICLE; BRAIN DAMAGE; CELL LOSS; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADJUVANTS, IMMUNOLOGIC; BRAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PEPTIDES; TIME FACTORS;

EID: 70449360324     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.171090     Document Type: Article

References (34)

1. McFarland HF. The lesion in multiple sclerosis: clinical, pathological, and magnetic resonance imaging considerations. J Neurol Neurosurg Psychiatry 1998;64(1 Suppl):S26-30.
2. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-846
3. Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47:1469-1476 (Pubitemid 26422538)
4. Barkhof F, McGowan JC, van Waesberghe JH, et al. Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: their contribution in understanding multiple sclerosis evolution. J Neurol Neurosurg Psychiatry 1998;64(1 Suppl):S77-9. (Pubitemid 28274442)
5. Barkhof F, Karas GB, van Walderveen MA. T1 hypointensities and axonal loss. Neuroimaging Clin N Am 2000;10:739-52, ix.
6. Filippi M. Magnetization transfer imaging to monitor the evolution of multiple sclerosis. Ital J Neurol Sci 1999;20:S232-40.
7. Paolillo A, Pozzilli C, Gasperini C, et al. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with "black holes," disease duration and clinical disability. J Neurol Sci 2000;174:85-91.
8. Bruck W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-793 (Pubitemid 27481551)
9. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin- echo MRI in multiple sclerosis. Neurology 1998;50:1282-1288 (Pubitemid 28240340)
10. Bitsch A, Kuhlmann T, Stadelmann C, et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 2001;49:793-796 (Pubitemid 32530247)
11. Ciccarelli O, Giugni E, Paolillo A, et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 1999;6:455-459 (Pubitemid 29371143)
12. Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001;57:731-733
13. Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000;55:185-192 (Pubitemid 30604616)
14. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-1247 (Pubitemid 32947383)
15. Barkhof F, van Waesberghe JH, Filippi M, et al. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001;124(Pt 7):1396-1402
16. Wolansky LJ, Haghighi MH, Sevdalis E, et al. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial. J Neuroimaging 2005;15:289-290 (Pubitemid 40863668)
17. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFN{beta}-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976-1983.
18. Minneboo A, Uitdehaag BM, Ader HJ, et al. Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. Neurology 2005;65:56-61. (Pubitemid 40967776)
19. van Walderveen MA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 1995;45:1684-1690
20. Rovaris M, Comi G, Ladkani D, et al. Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. Am J Neuroradiol 2003;24:75-81. (Pubitemid 36110104)
21. Fazekas F, Sorensen PS, Filippi M, et al. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler 2005;11:433-440 (Pubitemid 40984238)
22. Adams HP, Wagner S, Sobel DF, et al. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. Eur Neurol 1999;42:52-63. (Pubitemid 29317484)
23. Gómez-Choco M, Segal L, Alemany M, et al. Radiological outcome of new enhancing lesions by monthly 3T MRI with triple dose gadolinium: preliminary analysis of the BECOME study. American Academy of Neurology Annual Meeting, San Diego, California, 2006.
24. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002;58(4 Suppl):S3-9.
25. Cocco E, Marchi P, Floris G, et al. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis. Funct Neurol 2006;21:145-149 (Pubitemid 44823553)
26. Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004;251:407-413
27. Bagnato F, Gupta S, Richert ND, et al. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol 2005;62:1684-1688 (Pubitemid 41626663)
28. Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003;126(Pt 8):1782-1789 (Pubitemid 36917337)
29. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. Am J Neuroradiol 1998;19:675-683
30. Frank JA, Stone LA, Smith ME, et al. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol 1994;36(Suppl):S86-90.
31. Filippi M. Magnetic resonance imaing findings of a phase III trial comparing Betaferon with Copaxone treatments in relapsing-remitting multiple sclerosis. 18th Meeting of the European Neurological Society, 2008.
32. Parry A, Clare S, Jenkinson M, et al. White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis. J Neurol 2002;249:1279-1286 (Pubitemid 35025108)
33. Chen JT, Collins DL, Atkins HL, et al. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 2008;63:254-262
34. Wolansky L, Sheynzon V, Biswal B, et al. Magnetization transfer effect of fat suppression pulses on conspicuity of MS lesions at 3.0T: preliminary results of the "BECOME Trial." Annual Meeting of the ASNR, San Diego, California, 2006.